Application

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 90099348

Filing Date: 08/07/2020

To the Commissioner for Trademarks:

MARK: IN8BIO (Standard Characters, see mark)
The literal element of the mark consists of IN8BIO. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Incysus Therapeutics, Inc., a corporation of Delaware, having an address of
      79 Madison Avenue
      New York, New York 10001
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations, namely oncological preparations; Reagents, diagnostics and therapeutic preparations for medical use in oncology; Targeted medical preparations for use in oncology; Pharmaceutical preparations for use in the treatment of cancer and tumors; Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; Pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; Medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; Pharmaceutical and biological preparations comprised of modified T cells used for multiple modes of treatment against tumor resistance and immunosuppression
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Research, development, and evaluation of new products; Pharmaceutical, medicine, and vaccine research and development services; Technical research in the field of pharmaceutical studies; Laboratory analysis and research into new drugs and pharmaceutical products; Development of measuring and testing methods in the field of medicine; Design, development, research, and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; Research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; Providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; Scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Mark Jansen. Other appointed attorneys are All other attorneys of Fenwick & West LLP. Mark Jansen of Fenwick & West LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      801 California Street
      Mountain View, California 94041
      United States
      650-988-8500(phone)
      trademarks@fenwick.com
The docket/reference number is 37070-00070.
Mark Jansen submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Mark Jansen

PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@fenwick.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): lwilliams@fenwick.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $550 has been submitted with the application, representing payment for 2 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /William Ho/   Date: 08/06/2020
Signatory's Name: William Ho
Signatory's Position: President & CEO
Payment Sale Number: 90099348
Payment Accounting Date: 08/07/2020

Serial Number: 90099348
Internet Transmission Date: Fri Aug 07 08:53:32 ET 2020
TEAS Stamp: USPTO/BAS-X.XX.XXX.XXX-20200807085332804
125-90099348-740273ce90f48910df7d68e733d
76d3b2cf1bc5debaaed3301231497e32f6d58d-D
A-53329722-20200806162636752049